A clinical and pharmacokinetic study of high-dose carboplatin, paclitaxel, granulocyte colony-stimulating factor, and peripheral blood stem cells in patients with unresectable or metastatic cancer.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Seminars in Oncology

• Publication date

  1995-10-01

• Fields of study

  Medicine

• Identifiers
  PMID 7481867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-intensity chemotherapy with peripheral blood progenitor cell support.

  1994cited by this paper
• Phase II study of taxol in patients with untreated advanced non-small-cell lung cancer.

  1993cited by this paper
• Comparative effects of granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) on priming peripheral blood progenitor cells for use with autologous bone marrow after high-dose chemotherapy.

  1993cited by this paper
• A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy.

  1992cited by this paper
• Carboplatin: an active drug in metastatic breast cancer.

  1992cited by this paper
• Mobilization of peripheral blood progenitor cells by chemotherapy and granulocyte-macrophage colony-stimulating factor for hematologic support after high-dose intensification for breast cancer.

  1992cited by this paper
• Phase I study of taxol and granulocyte colony-stimulating factor in patients with refractory ovarian cancer.

  1992cited by this paper
• Sequential cycles of high-dose carboplatin administered with recombinant human granulocyte-macrophage colony-stimulating factor and repeated infusions of autologous peripheral-blood progenitor cells: a novel and effective method for delivering multiple courses of dose-intensive therapy.

  1992cited by this paper
• Autologous bone marrow transplantation for patients with relapsed Hodgkin's disease.

  1991cited by this paper
• Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer.

  1991cited by this paper
• Taxol: A unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms

  1990cited by this paper
• Autologous bone marrow transplantation in B-cell non-Hodgkin's lymphoma: very low treatment-related mortality in 100 patients in sensitive relapse.

  1990cited by this paper
• A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support.

  1989cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• Autologous bone marrow transplantation. Current status and future directions.

  1989cited by this paper
• High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.

  1988cited by this paper
• High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

  1987cited by this paper
• Letter: Creatinine clearance: bedside estimate.

  1973cited by this paper

• Carboplatin Enhances the Activity of Human Transient Receptor Potential Ankyrin 1 through the Cyclic AMP-Protein Kinase A-A-Kinase Anchoring Protein (AKAP) Pathways

  2019cites this paper
• Autologous hematopoietic stem cell transplantation following high-dose chemotherapy for non-rhabdomyosarcoma soft tissue sarcomas.

  2011cites this paper
• Peripheral Neuropathy Due to Chemotherapy and Radiation Therapy

  2006cites this paper
• Original Carboplatin toxic effects on the peripheral nervous system of the rat

  2005cites this paper
• Dose Escalation Study of Intravenous Estramustine Phosphate in Combination with Paclitaxel and Carboplatin in Patients with Advanced Prostate Cancer 1

  2003cites this paper
• Dose escalation study of intravenous estramustine phosphate in combination with Paclitaxel and Carboplatin in patients with advanced prostate cancer.

  2003cites this paper
• Aus der Klinik für Hämatologie, Onkologie und Klinische Immunologie der Heinrich-Heine-Universität Düsseldorf

  2002cites this paper
• High-dose carboplatin and regimen-related toxicity following autologous bone marrow transplant

  2002cites this paper
• Clinical Pharmacokinetics of Anticancer Drugs:focus on E7070, methotrexate and paclitaxel

  2002cites this paper
• Pharmacological considerations of primary alkylators.

  2002cites this paper
• Drug Interactions of Paclitaxel and Docetaxel and their Relevance for the Design of Combination Therapy

  2001cites this paper
• Paclitaxel, estramustine phosphate, and carboplatin in patients with advanced prostate cancer.

  2001cites this paper
• Phase I trial of multiple cycles of high-dose carboplatin, paclitaxel, and topotecan with peripheral-blood stem-cell support as front-line therapy.

  2001cites this paper
• Phase II trial of induction high-dose chemotherapy followed by surgical resection and radiation therapy for patients with marginally resectable non-small cell carcinoma of the lung.

  2000cites this paper
• Multi-institutional validation study of carboplatin dosing formula using adjusted serum creatinine level.

  2000cites this paper
• Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy.

  2000cites this paper
• [Carboplatin in cancer of the ovary].

  2000cites this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cites this paper
• Phase I trial of multiple cycles of high-dose chemotherapy supported by autologous peripheral-blood stem cells.

  1999cites this paper
• High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation

  1999cites this paper
• High dose chemotherapy for refractory urothelial carcinoma supported by peripheral blood stem cell transplantation.

  1999cites this paper
• Carboplatin toxic effects on the peripheral nervous system of the rat.

  1998cites this paper
• New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors.

  1998cites this paper
• Phase II study of "dose-dense" high-dose chemotherapy treatment with peripheral-blood progenitor-cell support as primary treatment for patients with advanced ovarian cancer.

  1998cites this paper
• Multiple cycles of high-dose chemotherapy for ovarian cancer.

  1998cites this paper
• Phase I and pharmacologic study of the combination paclitaxel and carboplatin as first-line chemotherapy in stage III and IV ovarian cancer.

  1997cites this paper
• Clinical Pharmacokinetics and Dose Optimisation of Carboplatin

  1997cites this paper
• A Comparative Review of Colony-Stimulating Factors

  1997cites this paper